This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
20
PCSK9 inhibitor(Alirocumab) was giving to subjects before PPCI and continued twice a month until 3 month after AMI
standard medications was giving to subjects according guidelines
Tongren Hospital, Shanghai
Shanghai, Shanghai Municipality, China
RECRUITINGShanghai tenth people's hospital
Shanghai, China
RECRUITINGmyocardial salvage index measured by MRI
Time frame: one week after PPCI
myocardial salvage index measured by MRI
Time frame: six months after PPCI
eject fraction measured by MRI
Time frame: one week after PPCI
eject fraction measured by MRI
Time frame: six month after PPCI
the change of serum level of TnI/T
Time frame: 0,6 ,12,18 , 24 ,30,and 36 hours after PPCI
LDL -C control rate
Time frame: the first month after PPCI
the serum lever of hsCRP
Time frame: Baseline (before PPCI)
the serum lever of hsCRP
Time frame: one week after PPCI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.